Adial Pharma-Backed Purnovate Selects PNV-5030 As Pain Management Candidate

·1 min read
  • Adial Pharmaceuticals Inc (NASDAQ: ADIL) has announced data in a preclinical model of pain reduction. Based on the data, Adial's subsidiary Purnovate Inc selected PNV-5030 as the lead compound for its program to develop pain management drugs.

  • PNV-5030 has been tested to be more than 1000-fold selective over the adenosine A1 receptor, which is known to have cardiovascular and central nervous system effects across several therapeutic indications.

  • PNV-5030 has demonstrated more than 50 times greater solubility than other known selective adenosine compounds of the same class.

  • In the most recent study, PNV-5030 was tested in a mouse model of somatic nociceptive pain.

  • PNV-5030 alone exhibited a significant pain reduction compared to the control group and a similar effect to 1mg/kg morphine.

  • PNV-5030 demonstrated a significant effect when administered with 1 mg/kg morphine compared to 1 mg/kg morphine alone.

  • Combined with 1 mg/kg morphine, PNV-5030 achieved a similar level of pain reduction to the reduction obtained with 2mg/kg morphine.

  • The results indicate the possibility of lowering the opioid dose to achieve a similar pain reduction.

  • The Company expects to advance PNV-5030 into clinical trials in 2022.

  • Price Action: ADIL shares are down 7.18% at $3.88 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting